Sign in

CIK 0001404281

  • Non-accelerated filer
  • Smaller reporting company

Eledon Pharmaceuticals, Inc.

Sign in to watch
Ticker
ELDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 949-238-8090
Business address
19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA, 92612
Former names
Eledon Pharmaceuticals, Inc., Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $4.48 ($8,960)
  7. 4 Open-market buy Chief Executive Officer bought 4,000 shares at $6.21 ($24,840)
  8. 3 Insider Initial Statement of Ownership
  9. 4 Open-market buy CHIEF FINANCIAL OFFICER bought 10,000 shares at $8.87 ($88,700)
  10. 4 Open-market buy Chief Executive Officer bought 3,000 shares at $8.01 ($24,030)
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 3 Insider Initial Statement of Ownership
  14. 4 Conversion See Explanation of Responses acquired 1,289,628 shares (conversion)
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale 10% owner sold 103,200 shares at $21.60 ($2,229,120)
  17. 4 Open-market buy 10% owner bought 92,040 shares at an average $25.44 ($2,341,714)
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 4 of 11 · 212 filings